{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T04:25:25.463099+00:00","company":{"ticker":"APUS","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc."},"pagination":{"limit":100,"returned":14,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Inscobee Inc. and Apimeds Inc.","detail":"settlement","count":1,"first_seen":"2026-05-04T23:59:59+00:00","last_seen":"2026-05-04T23:59:59+00:00","evidence_fact_ids":[21796]},{"display_name":"MindWave Innovations Inc.","detail":"merger","count":1,"first_seen":"2025-12-10T23:59:59+00:00","last_seen":"2025-12-10T23:59:59+00:00","evidence_fact_ids":[129497]}]},"facts":[{"fact_type":"executive_change","fact_key":"c35bd825d7","cik":1894525,"ticker":"APUS","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2026-05-05T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-05-04","interim":false,"role":"Co-Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Sungjoon Chae was appointed as Co-Chief Executive Officer at Apimeds Pharmaceuticals US, Inc..","evidence_excerpt":"On May 4, 2026, pursuant to a nomination by a stockholder of Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the \" Company \"), the board of directors of the Company (the \" Board \") appointed Sungjoon Chae to serve as Co-Chief Executive Officer of the Company, effective as of such date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-26-052036","anchor_url":"https://secwatch.observer/filing/0001213900-26-052036#claim-c35bd825d7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1894525/000121390026052036/0001213900-26-052036-index.htm"},{"fact_type":"material_agreement","fact_key":"0ac6a74a61dd19ca1aba3426ccba07e6f1ca2e48","cik":1894525,"ticker":"APUS","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2026-05-04T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Confidential Settlement and Mutual Release Agreement","agreement_type":"settlement","counterparty":"Inscobee Inc. and Apimeds Inc. (the Inscobee Parties)","effective_date":"2026-04-24","item_codes_triggered":["1.01"],"value_text":null},"claim":"Apimeds Pharmaceuticals US, Inc. entered into Confidential Settlement and Mutual Release Agreement with Inscobee Inc. and Apimeds Inc. (the Inscobee Parties) (effective 2026-04-24).","evidence_excerpt":"On April 24, 2026, Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “ Company ”), MindWave Innovations Inc, a Delaware corporation and a wholly owned subsidiary of the Company (“ MindWave ”), and Lokahi Therapeutics, Inc., a Nevada corporation (“ Lokahi ” and, together with the Company and MindWave, the “ Company Parties ”), together with Erik Emerson (“ Emerson ”), individually and in his capacity as Bio Business Representative under the Agreement and Plan of Merger, dated December 1, 2025 (the “ Merger Agreement ”), entered into a Confidential Settlement and Mutual Release Agreement (the “ Settlement Agreement ”), with Inscobee Inc., a South Korean corporation (“ Inscobee ”), and Apimeds Inc., a South Korean corporation and wholly owned subsidiary of Inscobee (“ Apimeds Korea ”, together with Inscobee, the “ Inscobee Parties ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-051125","anchor_url":"https://secwatch.observer/filing/0001213900-26-051125#claim-0ac6a74a61dd19ca1aba3426ccba07e6f1ca2e48","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1894525/000121390026051125/0001213900-26-051125-index.htm"},{"fact_type":"executive_change","fact_key":"0fe7214406","cik":1894525,"ticker":"APUS","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2026-05-04T23:59:59+00:00","payload":{"action":"resignation","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Jakap Koo departed as Director at Apimeds Pharmaceuticals US, Inc..","evidence_excerpt":"Under the Settlement Agreement, the Inscobee Parties have agreed to secure the resignation or removal of Mr. Koo.","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001213900-26-051125","anchor_url":"https://secwatch.observer/filing/0001213900-26-051125#claim-0fe7214406","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1894525/000121390026051125/0001213900-26-051125-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"e9d464af416a9835c5d813554efedd7c728a7432","cik":1894525,"ticker":"APUS","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2026-04-22T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2026-10-17","deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nyse_american","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2026-04-17","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Section 1007 of the NYSE American Listed Company Manual","reported_value":null,"rule_numbers":["1007"],"rules_cited_in_text":true},"claim":"Apimeds Pharmaceuticals US, Inc. received a nyse_american deficiency notice notice regarding late filing (rules 1007).","evidence_excerpt":"April 17, 2026, Apimeds\nPharmaceuticals US, Inc. (the “ Company ”) received a notice from the NYSE Regulation staff of the New York Stock Exchange\n(“ NYSE ”) indicating that the Company is not in compliance with NYSE’s continued listing requirements under the\ntimely filing criteria outlined in Section 1007 of the NYSE American Listed Company Manual as a result of the Company’s failure\nto timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “ Form 10-K ”). NYSE informed the\nCompany that the Company will have an initial cure period of six months from April","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-046671","anchor_url":"https://secwatch.observer/filing/0001213900-26-046671#claim-e9d464af416a9835c5d813554efedd7c728a7432","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1894525/000121390026046671/0001213900-26-046671-index.htm"},{"fact_type":"governance_change","fact_key":"75cc78fd89876ec222c9611adb20eb9781c4a6d5","cik":1894525,"ticker":"APUS","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2026-03-26T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":null,"item_codes_triggered":["5.03"],"summary_text":"Attempted amendment to the Amended and Restated Bylaws via stockholder written consent, which the company asserts is invalid."},"claim":"Apimeds Pharmaceuticals US, Inc.: Attempted amendment to the Amended and Restated Bylaws via stockholder written consent, which the company asserts is invalid.","evidence_excerpt":"Because the Stockholder Consent is invalid, the amendment to the Amended and Restated Bylaws of the Company made in connection with the Stockholder Consent is invalid.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-034786","anchor_url":"https://secwatch.observer/filing/0001213900-26-034786#claim-75cc78fd89876ec222c9611adb20eb9781c4a6d5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1894525/000121390026034786/0001213900-26-034786-index.htm"},{"fact_type":"governance_change","fact_key":"df14f225c2dce295a1fd5c62b52c239f05d4d67d","cik":1894525,"ticker":"APUS","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2026-03-25T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2026-03-20","item_codes_triggered":["5.03"],"summary_text":"Amended bylaws to allow majority voting power to fill board vacancies and to confirm amendments may be approved by majority voting power."},"claim":"Apimeds Pharmaceuticals US, Inc.: Amended bylaws to allow majority voting power to fill board vacancies and to confirm amendments may be approved by majority voting power (effective 2026-03-20).","evidence_excerpt":"Pursuant to the Consent, the Majority Stockholders also amended the Amended and Restated Bylaws of the Company, as amended to date, to (a) allow stockholders of the Company holding a majority of the voting power of the Company the power to fill vacancies on the Board and (b) confirm that amendments to the Company’s bylaws may be approved by a majority of the voting power of the Company.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-033832","anchor_url":"https://secwatch.observer/filing/0001213900-26-033832#claim-df14f225c2dce295a1fd5c62b52c239f05d4d67d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1894525/000121390026033832/0001213900-26-033832-index.htm"},{"fact_type":"material_agreement","fact_key":"39b62d27446d2089dd00c590d8a07edff5edf308","cik":1894525,"ticker":"APUS","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2025-12-10T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Securities Purchase Agreement","agreement_type":"notes_offering","counterparty":"Institutional Investor","effective_date":"2025-12-08","item_codes_triggered":["1.01"],"value_text":"Amendment to existing $120,900,000 senior convertible note agreement with 8% original issue discount"},"claim":"Apimeds Pharmaceuticals US, Inc. amended Securities Purchase Agreement with Institutional Investor valued at Amendment to existing $120,900,000 senior convertible note agreement with 8% original issue discount (effective 2025-12-08).","evidence_excerpt":"On December 8, 2025, the Acquiror and the Investor entered into Amendment No. 1 to the Securities Purchase Agreement (“ Amendment No. 1 ”), under which the parties (i) clarified how long the Acquiror is prohibited from entering into a variable rate transaction, (ii) expanded the notification rights of the Investor if another funding event occurs, and (iii) extended the date for the Acquiror to complete the Initial Closing (as such term is defined in the Securities Purchase Agreement).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-119893","anchor_url":"https://secwatch.observer/filing/0001213900-25-119893#claim-39b62d27446d2089dd00c590d8a07edff5edf308","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1894525/000121390025119893/0001213900-25-119893-index.htm"},{"fact_type":"material_agreement","fact_key":"9690c60e3d5d802ba8ff4700c1cc40564c912d1a","cik":1894525,"ticker":"APUS","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2025-12-10T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Agreement and Plan of Merger","agreement_type":"merger","counterparty":"MindWave Innovations Inc.","effective_date":"2025-12-01","item_codes_triggered":["1.01"],"value_text":"Correction of scrivener's errors related to Sections 2.05(b), 2.05(d), and 3.01(b); no other materia"},"claim":"Apimeds Pharmaceuticals US, Inc. amended Agreement and Plan of Merger with MindWave Innovations Inc. valued at Correction of scrivener's errors related to Sections 2.05(b), 2.05(d), and 3.01(b); no other materia (effective 2025-12-01).","evidence_excerpt":"The Acquiror is filing the corrected Merger Agreement as Exhibit 2.1 to this Amendment. No other material terms of the Merger Agreement are amended or modified.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-119893","anchor_url":"https://secwatch.observer/filing/0001213900-25-119893#claim-9690c60e3d5d802ba8ff4700c1cc40564c912d1a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1894525/000121390025119893/0001213900-25-119893-index.htm"},{"fact_type":"governance_change","fact_key":"de8a738ca8392c73ce879d828a2ebd9bdcbe63b4","cik":1894525,"ticker":"APUS","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2025-12-10T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-12-01","item_codes_triggered":["5.03"],"summary_text":"Corrected a scrivener's error in the Certificate of Designation for Series A Convertible Preferred Stock, changing the designated number of shares from 7,263,865 to 7,477,017."},"claim":"Apimeds Pharmaceuticals US, Inc.: Corrected a scrivener's error in the Certificate of Designation for Series A Convertible Preferred Stock, changing the designated number of shares from 7,263,865 to 7,477,017 (effective 2025-12-01).","evidence_excerpt":"The Company also determined that the Certificate of Designation filed with the Secretary of State of the State of Delaware on December 1, 2025, in connection with the Merger Agreement contained a scrivener’s error regarding the number of shares of Acquiror Preferred Stock designated as “Series A Convertible Preferred Stock.” The Certificate of Designation previously stated that there were 7,263,865 shares of Acquiror Preferred Stock designated as “Series A Convertible Preferred Stock”. The correct number of shares of Acquiror Preferred Stock designated as “Series A Convertible Preferred Stock” is 7,477,017.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-119893","anchor_url":"https://secwatch.observer/filing/0001213900-25-119893#claim-de8a738ca8392c73ce879d828a2ebd9bdcbe63b4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1894525/000121390025119893/0001213900-25-119893-index.htm"},{"fact_type":"equity_issuance","fact_key":"9f150c14594f9295cc97bc5f9347be5b40639c92","cik":1894525,"ticker":"APUS","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2025-12-02T23:59:59+00:00","payload":{"action":"warrant_issuance","consideration_text":"Underwriting/placement agent services","effective_date":"2025-12-01","item_codes_triggered":["3.02"],"purchaser":"E.F. Hutton & Co. LLC","security_type":"warrant","shares_text":"712,880 shares of Acquiror Common Stock"},"claim":"Apimeds Pharmaceuticals US, Inc. issued 712,880 shares of Acquiror Common Stock of warrant to E.F. Hutton & Co. LLC for Underwriting/placement agent services.","evidence_excerpt":"On December 1, 2025, the Acquiror issued a warrant to E.F. Hutton & Co. LLC, to purchase 712,880 shares of Acquiror Common Stock","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-25-117173","anchor_url":"https://secwatch.observer/filing/0001213900-25-117173#claim-9f150c14594f9295cc97bc5f9347be5b40639c92","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1894525/000121390025117173/0001213900-25-117173-index.htm"},{"fact_type":"governance_change","fact_key":"ecf49b02f8210a4fd83e5a25c93e830b69dae7b5","cik":1894525,"ticker":"APUS","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2025-10-16T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2025-10-15","item_codes_triggered":["5.03"],"summary_text":"Bylaws amended to allow shareholder action by written consent"},"claim":"Apimeds Pharmaceuticals US, Inc.: Bylaws amended to allow shareholder action by written consent (effective 2025-10-15).","evidence_excerpt":"On October 15, 2025, the board of directors of Apimeds Pharmaceuticals US, Inc. (the “Company”) amended the bylaws to allow shareholder action by written consent.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-099553","anchor_url":"https://secwatch.observer/filing/0001213900-25-099553#claim-ecf49b02f8210a4fd83e5a25c93e830b69dae7b5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1894525/000121390025099553/0001213900-25-099553-index.htm"},{"fact_type":"executive_change","fact_key":"e5cb12b209","cik":1894525,"ticker":"APUS","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2025-06-05T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-05-30","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Erick J. Frim was appointed as Chief Financial Officer at Apimeds Pharmaceuticals US, Inc..","evidence_excerpt":"On May 30, 2025, the Board of Directors of Apimeds Pharmaceuticals US, Inc. (the “Company”) appointed Erick J. Frim as Chief Financial Officer of the Company, replacing Mark Corrao.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-25-051567","anchor_url":"https://secwatch.observer/filing/0001213900-25-051567#claim-e5cb12b209","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1894525/000121390025051567/0001213900-25-051567-index.htm"},{"fact_type":"executive_change","fact_key":"bdb9334875","cik":1894525,"ticker":"APUS","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2025-06-05T23:59:59+00:00","payload":{"action":"replaced","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2025-05-30","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Erick J. Frim","successor_named":true},"claim":"Mark Corrao departed as Chief Financial Officer at Apimeds Pharmaceuticals US, Inc..","evidence_excerpt":"On May 30, 2025, the Board of Directors of Apimeds Pharmaceuticals US, Inc. (the “Company”) appointed Erick J. Frim as Chief Financial Officer of the Company, replacing Mark Corrao.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-25-051567","anchor_url":"https://secwatch.observer/filing/0001213900-25-051567#claim-bdb9334875","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1894525/000121390025051567/0001213900-25-051567-index.htm"},{"fact_type":"governance_change","fact_key":"9c84454ce9568a3214a35550145d31611da9c992","cik":1894525,"ticker":"APUS","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2025-04-15T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2025-04-11","item_codes_triggered":["5.03"],"summary_text":"Amended bylaws to add advance notice procedures, restrict special meetings, reduce quorum to 33 1/3%, eliminate written consent, set board size range, limit director removal to cause with 66 2/3% vote, require 66 2/3% vote to amend bylaws, and add Delaware forum selection clause."},"claim":"Apimeds Pharmaceuticals US, Inc.: Amended bylaws to add advance notice procedures, restrict special meetings, reduce quorum to 33 1/3%, eliminate written consent, set board size range, limit director removal to cause with 66 2/3% vote, require 66 2/3% vote to amend bylaws, and add Delaware forum selection clause (effective 2025-04-11).","evidence_excerpt":"On April 11, 2025, the Board of Directors (the “Board”) of Apimeds Pharmaceuticals US, Inc. (the “Company”) amended its bylaws to, among other things: (i) establish an advanced notice procedure for stockholder proposals and director nominations to be brought before an annual or special meeting of stockholders (Section 5); (ii) limit the circumstances under which a special meeting of the stockholders can be convened (Section 6(a)); (iii) reduce the quorum requirement to transact business at a meeting of the stockholders from a majority, to 33 1/3% of the outstanding shares of stock entitled to vote (Section 8); (iv) eliminate the ability of stockholders to act by written consent (Section 13); (v) set the range of the number of directors constituting the whole Board to not less than one and not more than seven in number (Section 15); (vi) limit the removal of directors to removal for cause only, requiring the affirmative vote of at least 66 2/3% of the voting power of all outstanding sha","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-032176","anchor_url":"https://secwatch.observer/filing/0001213900-25-032176#claim-9c84454ce9568a3214a35550145d31611da9c992","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1894525/000121390025032176/0001213900-25-032176-index.htm"}]}